Drug Trial Radar · NCT04509700
Rollover Study to Provide Continued Treatment for Participants With B-Cell Malignancies Previously Enrolled in Studies of Parsaclisib (INCB050465)
Last checked: Nov 19, 2026Latest source record: Jun 25, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
112
Actual
Start
Aug 3, 2020
Primary completion
Nov 5, 2026
Study completion Nov 5, 2026
Sponsor
- Lead sponsor
- Incyte CorporationIncyte (INCY)
- Sponsor type
- Industry
- First posted
- Aug 12, 2020
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 2, multicenter, open-label study to provide continued supply of parsaclisib as monotherapy or in combination therapy with itacitinib, ruxolitinib, or ibrutinib to participants from Incyte-sponsored studies of parsaclisib.
Conditions
- B-Cell Malignancies
Interventions
ParsaclisibDrug
Participants will continue on the same dose (1,2.5,5 OR 20 mg) and schedule of parsaclisib as that provided in the parent Protocol at the time of the rollover.
parsaclisib + itacitinibDrug
Participants will continue on the same dose (1,2.5,5 OR 20 mg) and schedule of parsaclisib and 100 mg of itacitinib as that provided in the parent Protocol at the time of the rollover.
parsaclisib + ruxolitinibDrug
Participants will continue on the same dose (1,2.5,5 OR 20 mg) and schedule of parsaclisib and the same dose of ruxolitinib that was provided in the parent Protocol at the time of the rollover.
parsaclisib + ibrutinibDrug
Participants will continue on the same dose (1,2.5,5 OR 20 mg) and schedule of parsaclisib and 140 mg of ibrutinib as that provided in the parent Protocol at the time of the rollover.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]Time frame: Through study completion, an average of 5 years
Locations
105 sites in 17 countries. Site status is shown where the registry gives one.
Uab Comprehensive Cancer Center
Birmingham, Alabama
University of Alabama At Birmingham
Birmingham, Alabama
Mayo Clinic Rochester
Phoenix, Arizona
University of Arizona Cancer Center-Out Pt.
Tucson, Arizona
City of Hope National Medical Center
Duarte, California
California Cancer Associates For Research and Excellence
Fresno, California
Innovative Clinical Research Institute
Long Beach, California
Rocky Mountain Cancer Center
Aurora, Colorado
Rush University Medical Center-Consultants in Hematology
Chicago, Illinois
University of Kansas Hospital Authority
Westwood, Kansas
Rcca Md, Llc
Bethesda, Maryland
Massachusetts General Hospital
Boston, Massachusetts
University of Michigan Cancer Center
Ann Arbor, Michigan
Hattiesburg Clinic Hematology
Hattiesburg, Mississippi
Saint Luke'S Hospital of Kansas City
Kansas City, Missouri
Hca Midwest Health-Research Medical Center
Kansas City, Missouri
Comprehensive Cancer Centers of Nevada
Las Vegas, Nevada
Roswell Park Cancer Institute
Buffalo, New York
Memorial Sloan Kettering Cancer Center
New York, New York
Duke University Medical Center
Durham, North Carolina
University Hospitals Case Medical Center
Cleveland, Ohio
Cleveland Clinic
Cleveland, Ohio
The Ohio State University
Columbus, Ohio
Knight Cancer Institute At Oregon Health and Science University
Portland, Oregon
Baylor Scott White Univeristy Medical Center
Dallas, Texas
University of Washington-Seattle Cancer Care Alliance
Seattle, Washington
Medical University of Vienna
Vienna, Austria
Cliniques Universitaires Ucl Saint-Luc
Brussels, Belgium
Universitair Ziekenhuis Gent (Uz Gent)
Ghent, Belgium
Az Groeninge
Kortrijk, Belgium
Universitaire Ziekenhuis Leuven - Gasthuisberg
Leuven, Belgium
University Hospital Hradec Kralove
Hradec Králové, Czechia
Univerzita Karlova V Praze 1. Lekarska Fakulta
Prague, Czechia
Fakultni Nemocnice V Motole
Prague, Czechia
University Hospital Kralovkse Vinohrady
Prague, Czechia
Aarhus University Hospital
Århus N, Denmark
Rigshospitalet
Copenhagen, Denmark
Sjaellands Universitetshospital
Roskilde, Denmark
Chru de Brest Hospital Morvan
Brest, France
Centre Antoine Laccassagne
Nice, France
Showing 40 of 105 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.